Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

Parth Gandhi, Isha Gandhi, Andrea Hoeschen, Wes Mosher, Margaret L. MacMillan, MD, Armin Rashidi, MD PhD, Najla H El Jurdi, MD, Alexander Khoruts, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Qing Cao, MS, Brian C. Betts, MD, Angela Panoskaltsis-Mortari, PhD, Chi Chen, Shernan G Holtan, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-140117

Published: 2020

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Blood (2020) 136 (Supplement 1): 44–46.

https://doi.org/10.1182/blood-2020-136337

Published: 2020

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

Bishwas Shrestha, PhD, Kelly Walton, Jordan Reff, Elizabeth M. Sagatys, MD, Nhan Tu, PhD, Justin C. Boucher, PhD, Tayyeb Ghafoor, BS, Joseph Pidala, MD, Bruce R. Blazar, MD, Claudio Anasetti, MD, Brian C. Betts, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 196.

https://doi.org/10.1182/blood-2019-124031

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Lia Perez, MD, Hugo F. Fernandez, MD, Farhad Khimani, MBBS, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Asmita Mishra, MD, Leonel Ochoa, MD, Brian C. Betts, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD

Blood (2017) 130 (Supplement 1): 1985.

https://doi.org/10.1182/blood.V130.Suppl_1.1985.1985

Published: 2017

Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD

Blood (2016) 128 (22): 3486.

https://doi.org/10.1182/blood.V128.22.3486.3486

Published: 2016

Journal Articles

CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen

Anandharaman Veerapathran, PhD, Micheal Schell, PhD, Francisca Beato, B.S, TzuHua Juan, MPH, Sean Yoder, M.S, Brian C Betts, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD

Blood (2015) 126 (23): 4286.

https://doi.org/10.1182/blood.V126.23.4286.4286

Published: 2015

Journal Articles

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Brian C Betts, MD, David Bastian, Hung Nguyen, PhD, Jessica Lauren Heinrichs, BS, MS, Yongxia Wu, MD PhD, Anandharaman Veerapathran, PhD, Marie C Lee, MD, Jack Singer, MD, Claudio Anasetti, MD, Xue-Zhong Yu, MD MS

Blood (2015) 126 (23): 1874.

https://doi.org/10.1182/blood.V126.23.1874.1874

Published: 2015

Journal Articles

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Michael T Tees, MD MPH, Brian C Betts, MD, Hugo F Fernandez, MD, Ryan Hillgruber, Ernesto Ayala, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 2475.

https://doi.org/10.1182/blood.V124.21.2475.2475

Published: 2014

Journal Articles

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Chiara Frairia, MD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Joseph Pidala, MD PhD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2500.

https://doi.org/10.1182/blood.V124.21.2500.2500

Published: 2014

Journal Articles

Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease

Joseph Pidala, MD PhD, Jongphil Kim, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2502.

https://doi.org/10.1182/blood.V124.21.2502.2502

Published: 2014

Journal Articles

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Lia Perez, MD, Teresa Field, MD PhD, Marcie L Riches, MD MS, Hugo F Fernandez, MD, Frederick L Locke, MD, Brian C Betts, MD, Joseph Pidala, MD PhD, Erika Elmer, CCRP, Francisca Beato, BS, Maritza Lienlaf, MS, Pedro Horna, MD, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2014) 124 (21): 1167.

https://doi.org/10.1182/blood.V124.21.1167.1167

Published: 2014

Journal Articles

CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses

Brian C Betts, MD, Anandharaman Veerapathran, PhD, Francisca Beato, BS, Harshani R Lawrence, PhD, Said M Sebti, PhD, Joseph A Pidala, MD, Claudio Anasetti, MD

Blood (2014) 124 (21): 3819.

https://doi.org/10.1182/blood.V124.21.3819.3819

Published: 2014

Journal Articles

Th17 Lymphocytes In Human Gvhd Target Tissues Are Associated With Disease Severity and Refractoriness To Systemic Glucocorticoid Therapy

Joseph Pidala, MD, MS, Elizabeth M. Sagatys, MD, Mark Lloyd, MS, Jongphil Kim, PhD, Binglin Yue, MS, Brian C Betts, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2054.

https://doi.org/10.1182/blood.V122.21.2054.2054

Published: 2013

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

Janus Kinase-2 Inhibition Induces Durable Tolerance to Alloantigen by Dendritic Cell-Stimulated Human T Cells, Yet Preserves Immunity to Recall Antigen

Brian C. Betts, MD, Omar Abdel-Wahab, MD, Shane A Curran, PhD, Erin T St. Angelo, Priya Koppikar, Glenn Heller, PhD, Ross L Levine, MD, James W Young, MD

Blood (2011) 118 (21): 1903.

https://doi.org/10.1182/blood.V118.21.1903.1903

Published: 2011

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

NARROW

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses

Th17 Lymphocytes In Human Gvhd Target Tissues Are Associated With Disease Severity and Refractoriness To Systemic Glucocorticoid Therapy

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Janus Kinase-2 Inhibition Induces Durable Tolerance to Alloantigen by Dendritic Cell-Stimulated Human T Cells, Yet Preserves Immunity to Recall Antigen

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only